Houston Team Finds Way to Hunt Down Spreading Breast Cancer

Scientists at UTHealth Houston have developed a molecular "smart missile" that hunts down and destroys spreading breast cancer cells, offering fresh hope for patients facing one of medicine's toughest challenges.

The research team, led by Dr. Mikhail Kolonin, created a peptide called BLMP6 that acts like a homing device for metastatic cancer cells. When they tested it in mice with triple-negative breast cancer, the peptide traveled straight to the spreading cancer cells while leaving healthy tissue untouched.

Triple-negative breast cancer strikes about 10 to 15% of all breast cancer patients and is especially common among young women. It's one of the most aggressive forms of the disease, and once it spreads, treatment options become extremely limited.

The breakthrough gets even more promising. When researchers attached a cancer-killing drug to BLMP6, mice showed dramatically reduced metastasis and lived longer. The peptide delivered the medicine precisely where it was needed, like a targeted delivery system that skips healthy neighborhoods and goes straight to the problem address.

Using artificial intelligence, the team discovered that BLMP6 locks onto a protein called fibulin-4, which shows up in high amounts on aggressive, spreading cancer cells. They confirmed this works with human tissue samples too, finding clear differences between invasive cancers and normal breast tissue.

"Most drugs that are available will kill primary tumor cells and maybe some metastatic cells, but they also have broad toxicity and lots of side effects," Kolonin explained. His team's approach changes that equation entirely.

The discovery matters because metastasis causes most cancer deaths. Once cancer spreads from its original location to other parts of the body, treatment becomes incredibly difficult. Right now, no drugs specifically target metastatic cells, leaving doctors with limited options that often come with severe side effects.

The Ripple Effect

This research opens two powerful doors at once. First, BLMP6 could become the foundation for new targeted therapies that destroy spreading cancer cells while sparing healthy tissue from collateral damage. Second, by attaching imaging dyes to the peptide, doctors could potentially spot metastatic cancer earlier and track it more accurately than current methods allow.

The team tested BLMP6 on tissue samples from patients with various breast cancer types, and the results held strong. The peptide consistently bound to aggressive, invasive cancers while ignoring non-invasive cancers and healthy tissue, suggesting the findings in mice will translate to human treatment.

While this research is still in preclinical stages, it represents a fundamental shift in how scientists think about fighting metastatic cancer. Instead of carpet-bombing the body with treatments that harm both sick and healthy cells, this approach offers precision targeting that could make treatment more effective and less punishing.

The path from mouse studies to human treatments takes time, but this discovery gives researchers a clear molecular target and a proven method for reaching it.